Mesa Laboratories
MLAB
127.93
-5.48
-4.11%
Mesa Laboratories
US · MLAB
#3485 by market cap
127.93
-5.48
-4.11%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 12 in the most recent period (2026/Q3).
- Total institutional ownership rose 5.1 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 97.30% +5.09pp
- Institutions
- 221 +12
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund69.51%
Hedge Fund17.85%
Public Company6.44%
Individual/Insider3.06%
Private Company2.06%
Government Pension Fund0.91%
Family Office/Trust0.31%
Insurance Company0.19%
Other1.04%
Top holders as of 2026-06-30
Long Path Partners, LP
8.49% · 477.13K sh
BlackRock
8.14% · 457.60K sh
Wasatch Advisors LP
6.89% · 387.13K sh
Victory Capital Management Inc.
4.92% · 276.57K sh
Vanguard Capital Management, LLC
4.20% · 236.21K sh
Boston Partners Global Investors, Inc.
4.74% · 265.15K sh
AQR Capital Management
3.60% · 202.10K sh
Geode Capital Management, LLC
2.95% · 165.74K sh
Ranger Investment Management, L.P.
3.11% · 173.99K sh
Dimensional Fund Advisors
2.92% · 163.91K sh
Diamond Hill Capital Management, LLC
2.78% · 155.77K sh
Raymond James Financial, Inc.
2.67% · 149.94K sh
Morgan Stanley
2.49% · 140.02K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 25 buys · 14 sells
| Name | Role | Stake |
|---|---|---|
| John Sullivan | Chairperson | 1.15% |
| John Sakys | Vice President | 0.67% |
| Brian Archbold | Senior Vice President of Operations & Continuous Improvement | 0.33% |
| Shiraz Ladiwala | Lead Independent Director | 0.22% |
| R. Tripeny | Independent Director | 0.16% |
| Jennifer Alltoft | Independent Director | 0.14% |
| Siddhartha Kadia | Chief Executive Officer | 0.13% |
| Shannon Hall | Independent Director | 0.12% |
| Mark Capone | Independent Director | 0.11% |
| Lyndsey Crennen | Chief Accounting Officer | 0.04% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | Sanket Shah | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-10-12 | John Sullivan | Chairperson | Other Disposition | -1,200 | -- |
| 2026-09-08 | Shiraz Ladiwala | Lead Independent Director | Other Derivative Acquisition | +2,510 | -- |
| 2026-09-08 | John Sullivan | Chairperson | Other Derivative Acquisition | +1,774 | -- |
| 2026-09-08 | R. Tripeny | Independent Director | Other Derivative Acquisition | +1,774 | -- |
| 2026-09-08 | Mark Capone | Independent Director | Other Derivative Acquisition | +2,423 | -- |
| 2026-09-08 | Shannon Hall | Independent Director | Other Derivative Acquisition | +1,774 | -- |
| 2026-08-26 | Gary Owens | Former Chief Executive Officer | Intent to Sell (Form 144) | -20,358 | $127.75 |
| 2026-08-20 | Gary Owens | Former Chief Executive Officer | Intent to Sell (Form 144) | -20,000 | $122.50 |
| 2026-08-14 | Shiraz Ladiwala | Lead Independent Director | Derivative Exercise and Retained | +3,810 | -- |
| 2026-08-14 | John Sullivan | Chairperson | Derivative Exercise and Retained | +2,784 | -- |
| 2026-08-14 | R. Tripeny | Independent Director | Derivative Exercise and Retained | +2,784 | -- |
| 2026-08-14 | Mark Capone | Independent Director | Derivative Exercise and Retained | +2,784 | -- |
| 2026-08-14 | Shannon Hall | Independent Director | Derivative Exercise and Retained | +2,784 | -- |
| 2026-08-14 | Jennifer Alltoft | Independent Director | Derivative Exercise and Retained | +2,784 | -- |
| 2026-08-12 | John Sullivan | Chairperson | Private Disposition | -7,093 | $112.80 |
| 2026-08-12 | R. Tripeny | Independent Director | Open Market Acquisition | +900 | $113.69 |
| 2026-08-12 | Siddhartha Kadia | Chief Executive Officer | Private Acquisition | +7,093 | $112.80 |
| 2026-06-21 | John Sakys | Vice President | Automatic Disposition | -2,827 | $89.50 |
| 2026-06-21 | Brian Archbold | Senior Vice President of Operations & Continuous Improvement | Open Market Disposition | -2,516 | $89.50 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Mesa Laboratories discussion 0 comments